查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613125

電腦輔助藥物發現市場：按類型、治療領域和最終用戶分類 - 2025-2030 年全球預測

Computer-aided Drug Discovery Market by Type (Ligand-Based Drug Design, Sequence-Based Approaches, Structure-Based Drug Design), Therapeutic Area (Cardiovascular Disease, Diabetes, Neurology), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年電腦輔助藥物發現市場規模為37.4億美元，預計2024年將達到40.8億美元，複合年成長率為9.71%，2030年將達到71.6億美元。

電腦輔助藥物發現 (CADD) 涉及使用計算方法和工具來幫助發現和最佳化新藥物化合物的過程。這種創新方法對於減少傳統藥物開發的時間和成本至關重要，使其成為尋求效率的製藥公司的關鍵必需品。 CADD 應用於藥物開發的各個階段，從標靶識別和驗證到先導化合物化合物最佳化和臨床前測試。最終用途主要來自製藥和生物技術公司、學術和研究機構以及 CRO（委外研發機構）。該市場是由慢性病患病率不斷上升、對精準醫療的日益重視以及人工智慧和機器學習技術的日益採用等因素所推動的。該領域的機會包括開發更複雜的演算法和平台，以提高藥物發現過程的準確性和速度。公司可以透過投資人工智慧驅動的平台、整合巨量資料分析以及擴大與學術機構和科技公司的合作來利用這些進步。然而，高昂的初始成本、資料隱私問題以及對高品質資料來源的需求等挑戰可能會阻礙成長。監管障礙和生物系統的複雜性等限制也可能阻礙準確的建模。隨著市場隨著技術進步而不斷發展，公司專注於虛擬篩檢、分子建模和資料整合等領域的創新至關重要。考慮到市場的本質，我們發現市場競爭格局非常激烈，既包括成熟的領導者，也包括創新的新進入者。獲得市場佔有率的最佳策略包括利用技術進步、建立戰略夥伴關係以及強調開發支持個人化醫療方法的患者特異性模型，並最終與行業向精準醫療的發展保持一致。

主要市場統計
基準年[2023] 37.4億美元
預測年份 [2024] 40.8億美元
預測年份 [2030] 71.6億美元
複合年成長率（%） 9.71%

市場動態：揭示快速發展的電腦輔助藥物發現市場的關鍵市場洞察

供需的動態交互作用正在改變電腦輔助藥物發現市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 製藥和生物製藥公司對藥物開發活動的日益關注
    • 管理臨床前研究期間產生的大量資料的需求日益成長
  • 市場限制因素
    • 實施電腦輔助藥物發現解決方案的成本高昂
  • 市場機會
    • 增加電腦輔助藥物發現解決方案的技術整合
    • 政府對創新技術採用的支持政策
  • 市場挑戰
    • 與電腦輔助藥物發現解決方案相關的各種替代技術的可用性

波特五力：駕馭電腦輔助藥物發現市場的策略工具

波特的五力框架是了解電腦輔助藥物發現市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：電腦輔助理解藥物發現市場的外部影響

外部宏觀環境因素在塑造電腦輔助藥物發現市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 電腦輔助了解藥物發現市場的競爭格局

對電腦輔助藥物發現市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣電腦輔助供應商在藥物發現市場的績效評估

FPNV定位矩陣是評估電腦輔助藥物發現市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

透過策略分析和電腦輔助建議，規劃您在藥物發現市場的成功之路

對於希望加強在全球市場的影響力的公司來說，藥物發現市場的電腦輔助策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 製藥和生物製藥公司對藥物開發活動的日益關注
      • 管理臨床前研究過程中產生的大量資料的需求日益成長。
    • 抑制因素
      • 實施電腦輔助藥物發現解決方案的成本高昂
    • 機會
      • 電腦輔助藥物發現解決方案中技術的進一步整合
      • 支持引進創新技術的政府政策
    • 任務
      • 與電腦輔助藥物發現解決方案相關的各種替代技術的可用性
  • 市場區隔分析
    • 類型：擴大使用基於配體的藥物設計來開發可以預測新化合物活性的模型
    • 最終用戶：電腦輔助藥物發現在了解生物過程和識別潛在新藥方面具有巨大潛力
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章電腦輔助藥物發現市場：按類型

  • 基於配體的藥物設計
  • 基於序列的方法
  • 基於結構的藥物設計

第 7 章：按治療領域分類的電腦輔助藥物發現市場

  • 心血管疾病
  • 糖尿病
  • 神經病學
  • 腫瘤學
  • 呼吸系統疾病

第8章電腦輔助藥物發現市場：按最終用戶

  • 生技公司
  • 製藥公司
  • 研究室

第 9 章美洲電腦輔助藥物發現市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章按電腦輔助區域分類的亞太藥物發現市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 電腦輔助的歐洲、中東和非洲藥物發現市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • MilliporeSigma 宣布推出 AIDDISON：用於高效藥物開發的開創性 SaaS 平台
    • 拜耳公司和 Google Cloud 合作透過量子化學推進新藥發現
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Accelrys, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim International GmbH
  • Chemical Computing Group Inc.
  • Dassault Systemes SE
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-5D693B46C018

The Computer-aided Drug Discovery Market was valued at USD 3.74 billion in 2023, expected to reach USD 4.08 billion in 2024, and is projected to grow at a CAGR of 9.71%, to USD 7.16 billion by 2030.

Computer-aided Drug Discovery (CADD) involves the use of computational methods and tools to aid in the process of discovering and optimizing new pharmaceutical compounds. This innovative approach is essential in reducing the time and cost associated with traditional drug development, making it a significant necessity for pharmaceutical companies striving for efficiency. CADD is applied throughout various stages of drug development, from target identification and validation to lead optimization and preclinical testing. The end-use scope primarily spans pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs). The market is driven by factors such as the increasing prevalence of chronic diseases, a growing emphasis on precision medicine, and the rising adoption of AI and machine learning technologies. Opportunities in this field include the development of more sophisticated algorithms and platforms that enhance the accuracy and speed of drug discovery processes. Companies can capitalize on these advancements by investing in AI-driven platforms, integrating big data analytics, and expanding collaborations with academic institutions and tech firms. However, challenges such as high initial costs, data privacy concerns, and the need for high-quality data sources can hinder growth. Limitations also include regulatory hurdles and the complexity of biological systems that may impede accurate modeling. The market is continuously evolving with technological advancements, making it crucial for businesses to focus on innovation in areas like virtual screening, molecular modeling, and data integration. Insights into the market's nature suggest a strong competitive landscape with both established leaders and innovative newcomers. The best strategies for capturing market share involve leveraging technological advancements, forging strategic partnerships, and emphasizing the development of patient-specific models to support personalized medicine approaches, ultimately aligning with the industry's trend towards precision therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 3.74 billion
Estimated Year [2024] USD 4.08 billion
Forecast Year [2030] USD 7.16 billion
CAGR (%) 9.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Computer-aided Drug Discovery Market

The Computer-aided Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising focus on drug development activities by pharmaceutical and biopharmaceutical companies
    • Increasing need to manage the large data generated during preclinical studies
  • Market Restraints
    • High cost of implementation of computer-aided drug discovery solutions
  • Market Opportunities
    • Rising integration of technologies in computer-aided drug discovery solutions
    • Supportive government policies for the adoption of innovative technologies
  • Market Challenges
    • Availability of wide alternative technologies associated with computer-aided drug discovery solutions

Porter's Five Forces: A Strategic Tool for Navigating the Computer-aided Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Computer-aided Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Computer-aided Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Computer-aided Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Computer-aided Drug Discovery Market

A detailed market share analysis in the Computer-aided Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Computer-aided Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Computer-aided Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Computer-aided Drug Discovery Market

A strategic analysis of the Computer-aided Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Computer-aided Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accelrys, Inc., AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., Boehringer Ingelheim International GmbH, Chemical Computing Group Inc., Dassault Systemes SE, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Schrodinger, Inc., Simulations Plus, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Computer-aided Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Ligand-Based Drug Design, Sequence-Based Approaches, and Structure-Based Drug Design.
  • Based on Therapeutic Area, market is studied across Cardiovascular Disease, Diabetes, Neurology, Oncology, and Respiratory Disease.
  • Based on End User, market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising focus on drug development activities by pharmaceutical and biopharmaceutical companies
      • 5.1.1.2. Increasing need to manage the large data generated during preclinical studies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of implementation of computer-aided drug discovery solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising integration of technologies in computer-aided drug discovery solutions
      • 5.1.3.2. Supportive government policies for the adoption of innovative technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of wide alternative technologies associated with computer-aided drug discovery solutions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing usage of ligand-based drug design to develop a model that can predict the activity of new compounds
    • 5.2.2. End User: High potential of computer-aided drug discovery to understand biological processes and identify potential new drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Computer-aided Drug Discovery Market, by Type

  • 6.1. Introduction
  • 6.2. Ligand-Based Drug Design
  • 6.3. Sequence-Based Approaches
  • 6.4. Structure-Based Drug Design

7. Computer-aided Drug Discovery Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Cardiovascular Disease
  • 7.3. Diabetes
  • 7.4. Neurology
  • 7.5. Oncology
  • 7.6. Respiratory Disease

8. Computer-aided Drug Discovery Market, by End User

  • 8.1. Introduction
  • 8.2. Biotechnology Companies
  • 8.3. Pharmaceutical Companies
  • 8.4. Research Laboratories

9. Americas Computer-aided Drug Discovery Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Computer-aided Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Computer-aided Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. MilliporeSigma Introduces AIDDISON: A Pioneering SaaS Platform for Streamlined Drug Development
    • 12.3.2. Bayer AG and Google Cloud Partner to Advance Drug Discovery Through Quantum Chemistry
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Accelrys, Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Chemical Computing Group Inc.
  • 8. Dassault Systemes SE
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Regeneron Pharmaceuticals, Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Schrodinger, Inc.
  • 19. Simulations Plus, Inc.
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 2. COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMPUTER-AIDED DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMPUTER-AIDED DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE-BASED APPROACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023